US 10047160
Anti-EGFRvIII antibodies and uses thereof
granted A61KA61K2039/505A61K2039/507
Quick answer
US patent 10047160 (Anti-EGFRvIII antibodies and uses thereof) held by REGENERON PHARMACEUTICALS, INC. expires Mon Aug 09 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue Aug 14 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Aug 09 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 13
- CPC classes
- A61K, A61K2039/505, A61K2039/507, A61K39/3955, A61K39/39558